Drug intelligence / Profile preview

TRS022

Development stage: Unknown
Lead developer: Zhejiang Teruisi Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TRS022 is a recombinant humanized monoclonal antibody targeting CD47, developed by Zhejiang Teruisi Pharmaceutical. CD47 is a cell surface protein that acts as a "don't eat me" signal by interacting with Signal Regulatory Protein Alpha (SIRPα) on macrophages, allowing cancer cells to evade immune destruction. TRS022 is designed to block this interaction, thereby enhancing macrophage-mediated phagocytosis and clearance of malignant cells. It is currently being investigated in Phase 1 clinical trials for the treatment of advanced malignant solid tumors.

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on TRS022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRS022.

Explore the full profile